Cellular immunotherapies are an exciting development in the treatment of cancer. In chimeric antigen receptor (CAR) T cell therapy, T cells are harvested from a patient's blood and then genetically engineered in vitro to express a synthetic receptor, known as 'chimeric antigen receptor', which binds to a specific antigen on the patient's tumour cells. After reinfusion, CAR enables the modified T cells to expand and activate effector functions upon recognition of the tumour antigen. This approach has shown remarkable results in treating relapsed or refractory B cell malignancies. 1 These 'living drugs' are currently manufactured with the use of viral vectors based on retro-or lentiviruses to transfer the CAR encoding DNA sequence into the T cell. Given that viral vectors integrate transgenes randomly into the genome, it is possible that other important genes may get disrupted. 2 A study published recently by Fraietta et al. 
were analysed. Strikingly, the CD8þ CAR T cell repertoire during tumour regression consisted almost exclusively of a single cell clone. In these single cell descendants the vector had inserted into a copy of the TET2 gene. Since the patient's other copy of TET2 had a missense mutation, this resulted in a T cell with drastically reduced TET2 protein levels.
TET2 is an enzyme that catalyzes the oxidation of 5-methylcytosine in DNA to 5-hydroxymethylcytosine. This epigenetic modification plays a pivotal role in regulating haematopoietic stem and progenitor cell (HSPC) self-renewal. Mutations are frequently found in clonal haematopoiesis of indeterminate potential (CHIP), myelodysplastic syndromes, or myeloproliferative neoplasms. 4 Very elegant work from Siddhartha Jaiswal, Kenneth Walsh and others has recently elucidated the impact of TET2 in the progression of atherosclerosis and healing after myocardial infarction. 5, 6 To assess the effect of altered TET2 expression Fraietta and colleagues compared TET2-disrupted CAR T cells to unmodified T cells. Even though TET2 biallelic dysfunction led only to modest global epigenetic changes, differences in DNA accessibility in several regulator genes important for T cell function were observed. TET2 knockdown in T cells from healthy individuals revealed a link between the absence of TET2 and a differentiation phenotype known as central memory. This phenotype is thought to counteract entering a dysfunctional state called 'exhaustion'. The latter is often associated with inefficient control of persisting infections and tumours. 7 Finally, Fraietta et al. demonstrate that TET2 dysfunction increased the levels of granzyme B and perforin expression which are both integral part of the cytotoxic T cell machinery. The authors conclude that targeting the epigenome in CAR T cells might be a promising approach to improve efficiency and persistence of bespoke cellular cancer therapies. Enhancing efficiency is a prime objective in the improvement of immunotherapies. Augmented potency however also correlates with increased treatment-related toxicity. Boosting anti-tumour effects through TET2 modification could therefore also cause serious adverse events in certain cases. The most common cardiovascular side effects associated with cancer immunotherapy include hypotension, arrhythmias, myocarditis, and in severe cases heart failure. They can be broadly divided into autoimmune or cytokine-associated toxicity. 8 Autoimmune toxicity is antigen-specific and occurs when T cells cross-react with antigens present on non-tumour tissue. These so called 'on target, off tumour' effects have been observed in clinical trials with modified T cells where a cross-reactivity against Titin led to fatal toxicity against cardiac tissue. 9 In patients treated with checkpoint-inhibitors myocarditis has been described in up to 0.27% when a combination of ipilimumab (anti-CTLA4) and nivolumab (anti-PD-1) was administered.
In two fatal cases selective clonal T cell populations that had infiltrated, the myocardium were identical to those present in tumours and skeletal muscle. 10, 11 Cytokine-associated toxicity, clinically defined as cytokine release syndrome (CRS), is non-antigen-specific and evoked by the rapid release of (pro-inflammatory) cytokines into the blood after high-level immune activation. The mechanism by which CRS triggers acute heart failure is still incompletely understood, but the condition seems to bear similarities to sepsis-induced cardiomyopathy. Recent studies have also described an involvement of endothelial cells and macrophages. 12 So far, little is known about possible long-term cardiovascular side effects of cancer immunotherapies. It is conceivable that an enhanced systemic inflammatory anti-tumour response might also influence (lowgrade) chronic inflammation such as atherosclerosis. Thus, even though the impact of TET2 deficiency on atherosclerosis and heart failure seems to be mainly mediated by macrophages and though TET2 mutations in humans are primarily restricted to the myeloid cell line, it might be interesting to also explore loss of TET2 in other leukocytes in the context of cardiovascular disease as well. 13 A broad range of genetic approaches are currently being explored for the treatment of cardiovascular diseases. CAR T cell therapy however is currently restricted to patients with malignant diseases. Whether applications to ameliorate or cure cardiovascular diseases can be developed remains to be seen. One could imagine various approaches, e.g. a direction against fibroblasts to reduce cardiac fibrosis, or targeting atherosclerotic lesion progression with CAR T regulatory cells.
In conclusion, the present paper demonstrates how a mutation of a gene associated with clonal haematopoiesis impacted T cell functions and improved the outcome of CAR T cell therapy. Future studies will need to address potential acute or chronic cardiovascular side effects of tumour immunotherapies, but also evaluate if engineered T cells might offer promising avenues for novel treatment approaches for cardiovascular diseases.
